Early safety study of LY4560736 in healthy adults and people with Alzheimer's disease
Tests how safe LY4560736 is in healthy adults and people with Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Key facts
- Where
- Bunkyō City and Ōbu, JapanSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07843459, who can take part
Where in Japan
- The University of Tokyo HospitalBunkyō City, JapanNo longer taking part
- National Center for Geriatrics and GerontologyŌbu, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07843459
- Record updated
- 8 October 2026
- Original description
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.Read full original descriptionShow less
A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.
Inclusion: Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study; To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent and born in Japan; To qualify as Chinese for this study, all four of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
Exclusion: Are receiving therapeutic antibodies or expected to initiate treatment with therapeutic antibodies during the study; Have a condition that predisposes the participant to an infection; Have a current or recent acute, active infection; Have active tuberculosis (TB), have or have had latent TB.